INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
May 07 2024 - 8:00AM
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a
clinical-stage immunology company focused on developing
treatments that harness a patient’s innate immune system to fight
disease, today announced that it will host a conference call on
Thursday, May 9, 2024, at 4:30 PM EDT to discuss results for its
first quarter ended March 31, 2024 and to provide a corporate
update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call. Please ask for the INmune Bio
Fourth Quarter Conference Call when reaching the operator.
Date: May 9, 2024Time: 4:30 PM Eastern TimeParticipant Dial-in:
1-800-343-5172 Participant Dial-in (international):
1-203-518-9856Conference ID: INMUNE
A live audio webcast of the call can be accessed by
clicking here or using this
link:https://viavid.webcasts.com/starthere.jsp?ei=1666877&tp_key=6505d73fc4
A transcript will follow approximately 24 hours from the
scheduled call. A replay will also be available through May 15th by
dialing 1-844-512-2921 or 1-412-317-6671 (international) and
entering PIN no. 1155727.
About INmune Bio Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on
developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in
clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. XPRO, the
first of several DN-TNF products, is in clinical trials to
determine if it can treat patients with Mild Alzheimer’s disease.
Additional therapeutic indications including d treatment-resistant
depression and oncology will be pursued when resources allow. The
Natural Killer Cell Priming Platform includes INKmune™, a therapy
developed to prime a patient’s NK cells to treat patients with
cancer. INKmune uses a precision medicine approach for the
treatment of a wide variety of hematologic and solid tumor
malignancies. The INKmune trial is enrolling patients into a US
Phase I/II trial in men with metastatic castrate resistant prostate
cancer. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858)
964-3720info@inmunebio.com
Investor Contact:
Jason NelsonCore IR(516) 842-9619 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2023 to Jul 2024